What I am working with: dizziness · semaglutide.
I would like the mechanism, because I want to be able to reason about the cases nobody has written about.
I have tried to reason it out from first principles and got to two contradictory conclusions.
So what is the mechanism, and how well established is it?
Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
Slower costs time and nothing else. The ceiling is the same.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsOn the detail: escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Put another way, liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
Nothing here is medical advice, and research-use compounds are not approved for human use.
The top of the schedule is not the target. The working dose is.
The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
Four half-lives between steps, minimum. Work it out for your agent.
The relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
Hold rather than escalate while symptoms are active. Always.
The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.
Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Stepping back is a normal adjustment, not a failure.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.